María Echave

  • Citations Per Year
Learn More
BACKGROUND Surgical bleeding can be associated with an increased risk of morbidity and mortality across all surgical areas. Thus, numerous products have been developed to achieve haemostasis. A flowable haemostatic matrix such as Floseal® can quickly and reliably stop bleeding across the full spectrum of bleeding scenarios. The aim of this study was to(More)
AIMS In Spain, the first line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) consists of calcium-based phosphate binders (CB). However, their use is associated with vascular calcification and an increased mortality risk. The aim of this study was to assess the incremental cost-effectiveness of second-line Lanthanum Carbonate (LC) treatment(More)
OBJECTIVES To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin. METHODS Based on clinical trial VELOUR results, a three-state Markov model (stable disease, progression and death) with 2-week cycle(More)
PMS66 PharMacoeconoMic analySiS of Different StrategieS of MonotheraPy With Biologic theraPieS in ruSSian PatientS With rheuMatoiD arthritiS Ryazhenov VV1, Gorokhova SG2 1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center of JSC Russian Railways, Moscow, Russia Objectives: To perform comparative pharmacoeconomic(More)
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. This study estimated the incremental cost-effectiveness ratio (ICER) of(More)